Zenocutuzumab Clinical Trials

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy trial)

Zeno (zenocutuzumab, or MCLA-128) is being developed for the potential treatment of NRG1 fusion (NRG1+) lung, pancreas and other cancers. The eNRGy trial, a phase 1/2 clinical trial is an ongoing open-label, multicenter trial enrolling patients with NRG1+ solid tumors. The FDA has accepted for review a Biologics License Application for Zeno for the treatment of NRG1+ non-small cell lung and pancreatic cancer (PDUFA date Feb. 4, 2025).

Further details about the eNRGy clinical trial for Zeno, including current trial sites, can be found on the clinical trial website at http://www.nrg1.com, or by calling Medical Information at 1-888-479-5385 or +1-857-347-5730.

More information is available at the clinicaltrials.gov website.

Zenocutuzumab Clinical Trials

Zenocutuzumab-zbco Granted FDA Breakthrough Therapy Designation for NRG1+ Cholangiocarcinoma; Data Highlighting Potential of Zenocutuzumab-zbco in NRG1+ Cholangiocarcinoma to be Presented at AACR-NCI-EORTC

Partner Therapeutics Receives EMA Approval of IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Hematopoietic Sub-syndrome of Acute Radiation Syndrome [H-ARS])

European Medicines Agency CHMP Recommends EU Approval of Partner Therapeutics IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Haematopoietic Sub-syndrome of Acute Radiation Syndrome)